Stockwatch: Valeant Attempts To Divert Attention
Executive Summary
A well-orchestrated build-up to the annual J.P. Morgan Healthcare Conference and subsequent rush of fundraisings was helped by the acquisition of Ariad by Takeda early last week. But the good times were derailed by a drug-pricing diversion, unleashed by the US president-elect.
You may also be interested in...
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan
Pharmaceutical manufacturers have been waiting for Trump’s ax to fall – and it finally did, on the final full day of the industry’s biggest business meeting of the year.
Debt-laden Valeant Sells Its Assets, More Divestments Likely
Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.
Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?
Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.